Dense Deposit Disease (DDD) Global Market Trends and Growth Outlook 2025-2035 - Genetic Testing and Personalized Medicine Offer Hope for Dense Deposit Disease Patients

The "Dense Deposit Disease Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035" has been added to ...
Business Wire

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
WDAF-TV

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia

CAMBRIDGE, Mass., Dec. 20, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today ...
Nasdaq

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 ...
MedCity News

Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Yale Daily News

Alexion buys Achillion

Alexion Pharmaceuticals will acquire New Haven-based pharmaceutical company Achillion Pharmaceuticals for an anticipated $930 million, the companies announced last week. The two companies develop rare ...